<DOC>
	<DOC>NCT00993798</DOC>
	<brief_summary>The objective is to identify the optimal dose of SABER-Bupivacaine for postoperative pain control in patients undergoing elective arthroscopic shoulder surgery on the basis of pharmacokinetics, efficacy and safety evaluations. The study duration consists of a screening period up to 14 days and a treatment period 14 days with a long term follow up visit at 6 months. The study will provide further data on safety.</brief_summary>
	<brief_title>An International Trial to Evaluate the Efficacy and Safety of SABER-Bupivacaine for Postoperative Pain Control in Patients Following Arthroscopic Shoulder Surgery</brief_title>
	<detailed_description />
	<mesh_term>Pain, Postoperative</mesh_term>
	<mesh_term>Bupivacaine</mesh_term>
	<criteria>Subacromial impingement syndrome MRI with intact rotator cuff Patients suitable for general anaesthesia Known major joint trauma, infection, avascular necrosis, chronic dislocation, inflammatory or degenerative glenohumeral arthropathy, glenohumeral arthritis, frozen shoulder or previous surgery of the affected shoulder Abnormal ECG Prolonged QT syndrome Current or regular use of analgesic medication for other indication(s)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Post operative pain</keyword>
	<keyword>Local anaesthesia</keyword>
	<keyword>Postoperative pain after arthroscopic shoulder surgery</keyword>
</DOC>